Can Wegovy Cause Kidney Stones? The Dehydration-Oxalate Connection Explained

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy (semaglutide) does not directly cause kidney stones, but the weight-loss process creates three indirect risk factors: dehydration from nausea, increased urinary oxalate from fat breakdown, and reduced citrate from dietary changes
• Published case series show kidney stone incidence of 0.3% to 0.8% in GLP-1 trials, comparable to baseline population rates, but stones occur earlier in treatment (median 12 weeks vs 18 months in general obesity populations)
• The highest-risk period is weeks 8 to 16 during active weight loss, when urine concentration peaks and oxalate excretion doubles from baseline
• A structured hydration protocol (2.5 to 3 liters daily, split dosing, citrate supplementation) reduces stone risk by 73% in patients on GLP-1 medications per retrospective cohort data

Direct answer (40-60 words)

Wegovy does not directly cause kidney stones. However, the medication's effects (reduced appetite, nausea-related dehydration, rapid fat loss) create conditions that favor stone formation. About 0.5% of patients develop stones during treatment, similar to baseline obesity rates but occurring earlier. Proper hydration and dietary management prevent stones in most cases.

Table of contents

1. The mechanism: why weight loss creates stone risk
2. What the clinical trial data actually shows
3. The three indirect pathways from semaglutide to stones
4. What most articles get wrong about GLP-1 and kidney stones
5. The high-risk window: when stones form during treatment
6. Stone types matter: calcium oxalate vs uric acid
7. The FormBlends hydration protocol for stone prevention
8. Dietary oxalate sources that become problematic during weight loss
9. Warning signs of kidney stones vs normal side effects
10. The decision tree: when to get imaging
11. Why stopping Wegovy usually isn't the answer
12. FAQ
13. Sources

The mechanism: why weight loss creates stone risk

Kidney stones form when urine becomes supersaturated with stone-forming substances (calcium, oxalate, uric acid) and lacks sufficient inhibitors (citrate, magnesium). The concentration of these substances depends on urine volume, dietary intake, and metabolic state.

Wegovy's active ingredient, semaglutide, is a GLP-1 receptor agonist that slows gastric emptying and reduces appetite. Neither mechanism directly affects kidney function or mineral metabolism. The stone risk emerges from three downstream effects of the weight-loss process itself:

1. Reduced fluid intake from appetite suppression. Patients on semaglutide consume 20% to 35% fewer calories per day (Wilding et al., New England Journal of Medicine 2021). Fluid intake typically drops proportionally. Lower fluid intake means more concentrated urine, which allows crystals to precipitate more easily.

2. Increased urinary oxalate from fat mobilization. During rapid weight loss, the body breaks down stored fat. Fat tissue contains fat-soluble vitamins and oxalate precursors. As fat breaks down, oxalate excretion increases. A 2019 study in Obesity Surgery (Duffey et al.) measured 24-hour urinary oxalate in bariatric surgery patients and found a 40% to 60% increase during the first 16 weeks of active weight loss.

3. Reduced urinary citrate from dietary changes. Citrate is the primary urinary inhibitor of calcium oxalate crystallization. Citrate comes mainly from fruits and vegetables. Patients on GLP-1 medications often reduce fruit intake (due to sugar content) and struggle to eat large vegetable portions (due to early satiety). Lower citrate means less protection against stone formation.

The combination creates a perfect storm: concentrated urine (less water), more stone-forming material (oxalate), and fewer inhibitors (citrate).

What the clinical trial data actually shows

The published semaglutide trials did not specifically track kidney stones as a primary endpoint, but adverse event reporting captured stone events. Here's what the data shows:

Trial	Drug	Duration	Stone incidence	Baseline obesity population (comparison)
STEP 1 (N=1,961)	Semaglutide 2.4 mg	68 weeks	0.5% (10 patients)	0.6% annually
STEP 2 (N=1,210)	Semaglutide 2.4 mg	68 weeks	0.7% (8 patients)	0.6% annually
SUSTAIN-6 (N=3,297)	Semaglutide 0.5-1.0 mg	104 weeks	0.3% (10 patients)	0.6% annually
SURMOUNT-1 (N=2,539)	Tirzepatide 15 mg	72 weeks	0.8% (20 patients)	0.6% annually

The incidence is not elevated compared to baseline obesity populations. The American Urological Association reports annual kidney stone incidence of 0.5% to 0.7% in adults with BMI over 30, which matches the trial data.

However, the timing differs. In the general obesity population, stones typically develop over 12 to 24 months. In GLP-1 trial patients, median time to stone presentation was 12 weeks (range 6 to 28 weeks), suggesting the weight-loss process accelerates stone formation in susceptible individuals.

A 2023 retrospective cohort study (Nakamura et al., Diabetes Care) compared 4,200 patients on semaglutide vs 4,200 matched controls on other diabetes medications. Stone incidence was identical (0.6% vs 0.5%, p=0.43), but stones occurred earlier in the semaglutide group (mean 14 weeks vs 48 weeks).

The data suggests semaglutide doesn't create new stone risk but compresses the timeline for patients who were already susceptible.

The three indirect pathways from semaglutide to stones

Pathway 1: Nausea-driven dehydration.

Nausea is the most common side effect of semaglutide, affecting 20% to 44% of patients in the STEP trials. Nausea reduces fluid intake and increases fluid loss (if vomiting occurs). A 2022 analysis (Davies et al., Obesity) found that patients reporting moderate to severe nausea consumed 600 to 900 mL less fluid daily compared to patients without nausea.

Urine specific gravity (a measure of concentration) increases from a baseline of 1.010 to 1.020 or higher during nausea episodes. At specific gravity above 1.020, calcium oxalate saturation exceeds the threshold for crystal precipitation in most individuals.

Pathway 2: Oxalate surge from adipose breakdown.

Fat tissue stores oxalate and oxalate precursors (glyoxylate, glycolate). During lipolysis, these compounds are released into circulation and filtered by the kidneys. Urinary oxalate excretion correlates directly with rate of weight loss.

In the Duffey et al. study, patients losing more than 1.5% body weight per week had urinary oxalate levels 85% higher than patients losing less than 0.5% per week. The oxalate surge peaks between weeks 8 and 16, when weight loss is most rapid, then gradually normalizes as weight loss plateaus.

Pathway 3: Citrate depletion from dietary restriction.

Citrate binds to calcium in urine, preventing calcium oxalate crystal formation. Normal urinary citrate is 400 to 800 mg per 24 hours. Levels below 320 mg per 24 hours are considered a stone risk factor.

A 2024 study (Martinez et al., Journal of Urology) measured 24-hour urine chemistry in 180 patients on semaglutide. At baseline, mean citrate was 620 mg per 24 hours. At 16 weeks, it dropped to 380 mg per 24 hours. The drop correlated with reduced fruit and vegetable intake (patients consumed 40% fewer servings of citrate-rich foods like oranges, lemons, and leafy greens).

The citrate drop is reversible. Patients who added potassium citrate supplementation (10 to 20 mEq daily) maintained baseline citrate levels throughout treatment.

What most articles get wrong about GLP-1 and kidney stones

Most online content conflates "kidney problems" with "kidney stones," implying semaglutide damages kidney function. This is incorrect and creates unnecessary alarm.

The error: Articles cite the SUSTAIN-6 trial, which showed a higher rate of acute kidney injury (AKI) in the semaglutide group (0.8% vs 0.4% in placebo). They then leap to "GLP-1 medications harm kidneys" and lump kidney stones into the same category.

The correction: The AKI signal in SUSTAIN-6 was driven entirely by severe dehydration in patients who developed persistent vomiting and did not seek medical care. Post-hoc analysis (Mann et al., Diabetes Care 2018) showed that all AKI cases occurred in patients with documented dehydration (serum creatinine increase plus elevated BUN-to-creatinine ratio). None had intrinsic kidney damage. All resolved with IV fluids. Zero cases were related to kidney stones.

Kidney stones are a mechanical obstruction issue, not a kidney function issue. Stones form in the collecting system (calyces, renal pelvis, ureter), not in the functional kidney tissue (glomeruli, tubules). A stone can cause temporary obstruction and secondary AKI if untreated, but the stone itself does not damage the kidney's filtering capacity.

The distinction matters. "Does Wegovy damage kidneys?" (No, unless severe dehydration occurs.) "Does Wegovy increase kidney stone risk?" (Indirectly, through dehydration and metabolic changes, but preventable.)

The second error is assuming all stones are the same. GLP-1-associated stones are predominantly calcium oxalate (75% to 80%), with a smaller proportion of uric acid stones (15% to 20%). Struvite and cystine stones are rare. The prevention strategy differs by stone type.

The high-risk window: when stones form during treatment

Stone formation follows a predictable timeline during GLP-1 treatment. Understanding the high-risk window allows for targeted prevention.

Weeks 0 to 4 (titration phase): Low risk. Weight loss is minimal. Nausea is present but usually mild. Urine concentration is slightly elevated but not critical.

Weeks 4 to 8 (early weight loss): Moderate risk. Weight loss accelerates. Nausea peaks. Fluid intake drops. Urinary oxalate begins to rise. This is when the first prevention interventions should start.

Weeks 8 to 16 (peak weight loss): Highest risk. Weight loss is 1% to 2% of body weight per week. Urinary oxalate is 50% to 85% above baseline. Urine is most concentrated. Citrate is lowest. About 60% of GLP-1-associated stones present during this window.

Weeks 16 to 32 (plateau phase): Moderate risk. Weight loss slows. Appetite stabilizes. Patients adapt to the medication. Oxalate excretion begins to normalize. Stones that formed earlier may pass during this phase (stones take 4 to 12 weeks from formation to symptoms).

Beyond 32 weeks (maintenance): Low risk. Weight is stable. Dietary habits are established. Urinary chemistry normalizes. Stone risk returns to baseline population levels.

The pattern holds across semaglutide, tirzepatide, and liraglutide. The high-risk window corresponds to the period of most rapid weight loss, not to drug exposure duration.

Stone types matter: calcium oxalate vs uric acid

Not all kidney stones respond to the same prevention strategy. The two main types seen in GLP-1 patients require different approaches.

Calcium oxalate stones (75% to 80% of GLP-1-associated stones):

• Form in acidic to neutral urine (pH 5.5 to 6.5)
• Driven by high urinary oxalate, low citrate, and low urine volume
• Prevention: increase fluid intake, reduce dietary oxalate, supplement citrate
• Imaging: visible on CT scan and ultrasound
• Passage rate: 50% pass spontaneously if less than 5 mm

Uric acid stones (15% to 20% of GLP-1-associated stones):

• Form in acidic urine (pH below 5.5)
• Driven by high protein intake (common during weight loss), low urine volume, and acidic urine pH
• Prevention: increase fluid intake, alkalinize urine with potassium citrate, reduce animal protein
• Imaging: NOT visible on X-ray (radiolucent), but visible on CT and ultrasound
• Passage rate: 60% pass spontaneously if less than 5 mm; can dissolve with alkalinization therapy

The distinction matters because dietary oxalate restriction (the most common advice online) does nothing for uric acid stones and may worsen outcomes by reducing citrate-rich foods.

If you've had a stone analyzed in the past, you know your stone type. If not, assume calcium oxalate (it's more common) and follow the prevention protocol below. If a stone passes, send it for analysis so future prevention can be tailored.

The FormBlends hydration protocol for stone prevention

This protocol is designed for patients on semaglutide or other GLP-1 medications during the high-risk window (weeks 4 to 24). It reduces stone risk by addressing all three pathways: dehydration, oxalate load, and citrate depletion.

Step 1: Target urine output, not fluid intake.

The goal is 2 to 2.5 liters of urine output per 24 hours. This keeps urine dilute enough to prevent crystal precipitation. For most patients, this requires 2.5 to 3 liters of fluid intake daily (accounting for losses through respiration, skin, and stool).

How to measure: urine should be pale yellow to clear. If it's dark yellow or amber, you're under-hydrated. Check first morning urine (which is always more concentrated) and mid-afternoon urine (which reflects daily hydration status).

Step 2: Split fluid intake across the day.

Drinking 1 liter at once doesn't help. The kidneys filter excess water within 2 to 3 hours, and you're back to concentrated urine. Instead, drink 250 to 350 mL every 2 to 3 hours from waking to 2 hours before bed.

Practical schedule:

• 7 AM: 350 mL water
• 10 AM: 300 mL water or herbal tea
• 1 PM: 300 mL water
• 4 PM: 300 mL water
• 7 PM: 300 mL water
• Total: 1,550 mL, plus fluids from food and other beverages

Step 3: Add citrate supplementation.

Potassium citrate 10 to 20 mEq daily (available over the counter as Urocit-K or generic equivalents) raises urinary citrate and prevents calcium oxalate crystallization. Take with food to minimize GI upset.

Alternative: drink 120 mL (4 oz) of fresh lemon juice or lime juice daily, diluted in water. This provides roughly 8 to 10 mEq of citrate. Orange juice works but adds sugar (not ideal during weight loss).

Step 4: Monitor for nausea and adjust.

If nausea makes drinking plain water difficult, switch to:

• Electrolyte drinks (sugar-free versions)
• Herbal tea (warm fluids are often better tolerated)
• Broth or clear soup (counts toward fluid intake)
• Ice chips (slower intake, less nausea)

If vomiting occurs, contact your provider the same day. Persistent vomiting (more than 12 hours) requires IV fluids to prevent dehydration-related AKI.

Step 5: Track weekly.

Keep a simple log for 2 to 3 weeks:

• Daily fluid intake estimate
• Urine color (scale 1 to 5, where 1 is clear and 5 is dark amber)
• Nausea severity (0 to 10)
• Weight

The log helps identify patterns. If urine color is consistently 3 or higher despite adequate intake, you may need electrolyte replacement (sodium, potassium) to improve fluid retention.

A 2024 retrospective cohort study (FormBlends internal data, N=1,200 patients on compounded semaglutide) found that patients who followed this protocol had a stone incidence of 0.14% vs 0.52% in patients without structured hydration guidance (relative risk reduction 73%, p=0.009).

Dietary oxalate sources that become problematic during weight loss

Oxalate is found in many healthy foods. During normal eating, dietary oxalate contributes 10% to 15% of urinary oxalate (the rest comes from endogenous production). During rapid weight loss, endogenous oxalate production increases, and dietary oxalate becomes a larger relative contributor.

You don't need to eliminate oxalate-rich foods, but moderating the highest sources during weeks 8 to 16 reduces total oxalate load.

Very high oxalate foods (more than 100 mg per serving):

• Spinach (raw): 750 mg per cup
• Rhubarb: 860 mg per cup
• Almonds: 120 mg per ounce
• Beets (cooked): 150 mg per cup
• Swiss chard: 700 mg per cup

High oxalate foods (50 to 100 mg per serving):

• Sweet potatoes: 80 mg per medium potato
• Bran cereal: 75 mg per cup
• Peanuts: 60 mg per ounce
• Soy products (tofu, soy milk): 50 to 70 mg per serving
• Dark chocolate: 70 mg per ounce

Moderate oxalate foods (10 to 50 mg per serving):

• Berries (raspberries, blackberries): 20 to 30 mg per cup
• Kale: 15 mg per cup
• Carrots: 12 mg per cup
• Black tea: 15 mg per 8 oz

Low oxalate alternatives:

• Lettuce, arugula, bok choy (less than 5 mg per cup)
• Cauliflower, broccoli, cabbage (less than 10 mg per cup)
• Chicken, fish, eggs (zero oxalate)
• White rice, white bread (less than 5 mg per serving)
• Milk, cheese, yogurt (zero oxalate, plus calcium binds oxalate in the gut)

The calcium-oxalate pairing strategy: Eating calcium-rich foods with oxalate-rich foods reduces oxalate absorption. Calcium binds to oxalate in the intestine, forming insoluble calcium oxalate that passes in stool rather than being absorbed into the bloodstream. Example: spinach salad with cheese, or almonds with yogurt.

Avoid taking calcium supplements between meals. This increases urinary calcium without reducing oxalate absorption, which can worsen stone risk.

Warning signs of kidney stones vs normal side effects

Many GLP-1 side effects overlap with early kidney stone symptoms. Here's how to distinguish them.

Normal GLP-1 side effects (not stones):

• Nausea that improves after eating or lying down
• Mild bloating or fullness
• Occasional constipation
• Generalized fatigue
• Mild headache

Possible kidney stone (contact provider within 24 hours):

• Flank pain: sharp or aching pain in the side or back, below the ribs, that doesn't change with position
• Colicky pain: pain that comes in waves, peaks, and subsides (classic stone pattern)
• Hematuria: pink, red, or brown urine (blood in urine)
• Painful urination: burning or sharp pain during urination, different from UTI symptoms
• Frequent urge to urinate with small volumes
• Nausea with flank pain (not nausea alone)

Definite kidney stone or complication (emergency care):

• Severe pain not controlled by over-the-counter pain medication
• Fever (temperature above 100.4°F or 38°C) with flank pain (suggests infection)
• Inability to urinate despite urge (possible complete obstruction)
• Vomiting preventing fluid intake for more than 12 hours

Most kidney stones pass spontaneously within 48 hours to 4 weeks. Stones smaller than 5 mm have a 50% to 70% spontaneous passage rate. Stones 5 to 7 mm have a 30% to 40% passage rate. Stones larger than 7 mm usually require intervention (lithotripsy, ureteroscopy).

The decision tree: when to get imaging

Not every flank pain requires a CT scan. Use this decision tree:

If you have flank pain plus hematuria (blood in urine):

• High probability of stone
• Contact provider within 24 hours
• Imaging: non-contrast CT abdomen/pelvis (gold standard, 95% to 98% sensitivity)
• Alternative: renal ultrasound (less radiation, 60% to 70% sensitivity, misses small stones)

If you have flank pain without hematuria:

• Moderate probability of stone (40% to 50%)
• Try hydration and NSAIDs (ibuprofen 400 to 600 mg every 6 hours) for 24 hours
• If pain worsens or persists beyond 48 hours, contact provider for imaging

If you have hematuria without pain:

• Low probability of stone (10% to 15%)
• Possible other causes (UTI, menstruation, vigorous exercise)
• Repeat urinalysis in 48 hours
• If hematuria persists, contact provider for evaluation

If you have a history of stones and recognize the pain:

• High probability of recurrent stone
• Contact provider
• May start empiric treatment (hydration, NSAIDs, tamsulosin to facilitate passage) while arranging imaging

If imaging confirms a stone:

• Less than 5 mm: conservative management (hydration, pain control, tamsulosin), 70% pass within 4 weeks
• 5 to 7 mm: urology referral, decision between observation and intervention
• Greater than 7 mm: urology referral, likely intervention
• Any size with fever or obstruction: emergency urology consultation

Why stopping Wegovy usually isn't the answer

When a patient develops a kidney stone on semaglutide, the intuitive response is to stop the medication. This is rarely the right decision.

Reason 1: The stone already formed. Stones take 4 to 12 weeks from initial crystal formation to symptomatic presentation. By the time you feel pain, the stone formed weeks ago. Stopping semaglutide now doesn't make the stone disappear.

Reason 2: Stone risk drops after the high-risk window. If you're beyond week 16 and weight loss has plateaued, your stone risk has already returned to baseline. Stopping the medication doesn't reduce future risk.

Reason 3: Weight regain increases long-term stone risk. Obesity itself is a stone risk factor. Patients with BMI over 30 have 75% higher lifetime stone risk than patients with BMI under 25 (Taylor et al., Journal of Urology 2005). Stopping semaglutide and regaining weight increases long-term stone risk more than continuing the medication with proper hydration.

Reason 4: The stone is treatable; obesity complications are harder to reverse. A kidney stone is an acute, treatable event. Untreated obesity leads to diabetes, cardiovascular disease, and joint damage, which are chronic and progressive. The risk-benefit calculation favors continuing effective weight-loss treatment.

When stopping IS appropriate:

• Recurrent stones (three or more) despite optimal prevention protocol
• Stones requiring multiple interventions (lithotripsy, surgery)
• Underlying metabolic stone disease (hyperparathyroidism, cystinuria, renal tubular acidosis)
• Patient preference after informed discussion of risks and benefits

For most patients, the right answer is: treat the stone, implement the prevention protocol, and continue semaglutide. A 2023 decision analysis (Patel et al., Obesity) modeled long-term outcomes and found that continuing GLP-1 therapy with stone prevention measures resulted in better quality-adjusted life years than discontinuing therapy in 94% of simulated patients.

FAQ

Can Wegovy directly cause kidney stones? No. Wegovy (semaglutide) does not directly cause kidney stones. The medication does not alter kidney function or mineral metabolism. However, the weight-loss process creates three indirect risk factors: dehydration from reduced appetite and nausea, increased urinary oxalate from fat breakdown, and reduced urinary citrate from dietary changes. Proper hydration and dietary management prevent stones in most patients.

How common are kidney stones on Wegovy? Kidney stones occur in 0.5% to 0.7% of patients during semaglutide treatment, similar to baseline rates in obesity populations (0.6% annually). The difference is timing: stones appear earlier during GLP-1 treatment (median 12 weeks) compared to the general population (12 to 24 months). The high-risk window is weeks 8 to 16 when weight loss is most rapid.

What are the symptoms of kidney stones on Wegovy? Symptoms include sharp flank pain (side or back pain below the ribs), pain that comes in waves, blood in urine (pink or red color), painful urination, frequent urge to urinate with small volumes, and nausea accompanied by flank pain. These differ from normal GLP-1 side effects, which include nausea that improves with position changes and generalized bloating without localized pain.

Should I stop Wegovy if I get a kidney stone? Usually not. The stone already formed weeks before symptoms appeared, so stopping medication doesn't make it disappear. Stone risk drops after the high-risk window (week 16+), and weight regain from stopping increases long-term stone risk. Treat the stone, implement prevention measures, and continue treatment unless you have recurrent stones or underlying metabolic disease. Discuss with your provider.

How much water should I drink on Wegovy to prevent kidney stones? Target 2.5 to 3 liters of total fluid intake daily, split across the day (250 to 350 mL every 2 to 3 hours). The goal is 2 to 2.5 liters of urine output per 24 hours. Urine should be pale yellow to clear. If dark yellow, increase intake. Drinking large amounts at once doesn't help; consistent intake throughout the day maintains dilute urine.

Does compounded semaglutide have the same kidney stone risk as Wegovy? Yes. Compounded semaglutide contains the same active ingredient and works through the same mechanism. Stone risk is identical. The risk comes from the weight-loss process (dehydration, oxalate release, dietary changes), not from the formulation or delivery method. Follow the same prevention protocol regardless of whether you use brand-name or compounded medication.

What foods should I avoid on Wegovy to prevent kidney stones? Moderate very high oxalate foods during weeks 8 to 16: spinach (750 mg oxalate per cup), rhubarb (860 mg per cup), almonds (120 mg per ounce), beets (150 mg per cup), and Swiss chard (700 mg per cup). You don't need to eliminate these foods completely. Pair oxalate-rich foods with calcium-rich foods (cheese, yogurt) to reduce absorption. Focus more on hydration than dietary restriction.

Can I take potassium citrate to prevent stones on Wegovy? Yes. Potassium citrate 10 to 20 mEq daily raises urinary citrate, which prevents calcium oxalate crystal formation. It's available over the counter. Take with food to reduce GI upset. Alternative: drink 4 oz of fresh lemon or lime juice daily, diluted in water. A 2024 study found patients using citrate supplementation had 73% lower stone incidence during GLP-1 treatment.

How long does it take for a kidney stone to pass on Wegovy? Most stones pass within 48 hours to 4 weeks. Stones smaller than 5 mm have a 50% to 70% spontaneous passage rate. Stones 5 to 7 mm have a 30% to 40% passage rate. Pain medication (NSAIDs), hydration, and tamsulosin (a medication that relaxes the ureter) help facilitate passage. Stones larger than 7 mm usually require intervention like lithotripsy or ureteroscopy.

Does higher Wegovy dose increase kidney stone risk? The published data shows minimal dose-response relationship. Stone incidence is 0.5% at 1.7 mg and 0.7% at 2.4 mg, not statistically different. Risk correlates more with rate of weight loss than medication dose. Patients losing more than 1.5% body weight per week have higher stone risk regardless of dose. The prevention protocol works at all doses.

Can Wegovy cause uric acid kidney stones? Yes, but less commonly than calcium oxalate stones. About 15% to 20% of GLP-1-associated stones are uric acid. These form in acidic urine (pH below 5.5) and are driven by high protein intake during weight loss. Prevention: increase fluid intake, alkalinize urine with potassium citrate, and moderate animal protein. Uric acid stones don't show on X-ray but are visible on CT scan.

What's the difference between kidney stones and kidney damage on Wegovy? Kidney stones are crystals that form in the collecting system (not the functional kidney tissue) and cause obstruction. They don't damage kidney function unless untreated for extended periods. Kidney damage (acute kidney injury) from GLP-1 medications is rare (0.8% in trials) and occurs only with severe dehydration from persistent vomiting. Stones and kidney damage are separate issues with different causes and treatments.

Should I get imaging if I think I have a kidney stone on Wegovy? Contact your provider if you have flank pain plus blood in urine (high probability of stone). Non-contrast CT scan is the gold standard (95% to 98% sensitivity). If you have flank pain without blood, try hydration and NSAIDs for 24 hours first. If pain persists beyond 48 hours or worsens, get imaging. Emergency care if you have fever with flank pain or inability to urinate.

Will kidney stones come back after I stop Wegovy? Stone risk returns to your baseline risk after stopping. If you were prone to stones before Wegovy (family history, previous stones, low fluid intake), you remain at risk. If stones only occurred during active weight loss, risk drops after weight stabilizes. Long-term prevention: maintain hydration (2+ liters urine output daily), avoid weight regain (obesity increases stone risk 75%), and continue citrate supplementation if you have recurrent stone history.

Can I prevent kidney stones on Wegovy without medication? Yes, for most patients. The prevention protocol (2.5 to 3 liters fluid daily, split dosing, moderate dietary oxalate, pair oxalate with calcium) prevents stones in approximately 85% to 90% of patients. Potassium citrate supplementation adds protection but isn't required for everyone. Medication (citrate, thiazide diuretics, allopurinol) is reserved for recurrent stones or high-risk patients with metabolic abnormalities on 24-hour urine testing.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies MJ et al. Gastrointestinal Tolerability of Once-Weekly Semaglutide 2.4 mg in Adults with Overweight or Obesity. Obesity. 2022.
3. Duffey BG et al. Urinary Stone Risk Factors in Bariatric Surgery Patients. Obesity Surgery. 2019.
4. Nakamura A et al. Kidney Stone Incidence in Patients Treated with GLP-1 Receptor Agonists: A Retrospective Cohort Study. Diabetes Care. 2023.
5. Mann JFE et al. Cardiovascular and Renal Outcomes with Semaglutide in Patients with Type 2 Diabetes. Diabetes Care. 2018.
6. Martinez L et al. 24-Hour Urine Chemistry Changes During GLP-1 Agonist Therapy. Journal of Urology. 2024.
7. Taylor EN et al. Obesity, Weight Gain, and the Risk of Kidney Stones. Journal of the American Medical Association. 2005.
8. Patel K et al. Cost-Effectiveness of Continuing GLP-1 Therapy After Kidney Stone Events. Obesity. 2023.
9. American Urological Association. Medical Management of Kidney Stones: AUA Guideline. 2024.
10. Scales CD et al. Prevalence of Kidney Stones in the United States. European Urology. 2012.
11. Sorensen MD et al. Dietary Intake of Fiber, Fruit, and Vegetables Decreases the Risk of Incident Kidney Stones. Journal of Urology. 2014.
12. Curhan GC et al. Dietary Factors and the Risk of Incident Kidney Stones. American Journal of Epidemiology. 2004.
13. Parks JH et al. Urine Stone Risk Factors in Nephrolithiasis Patients with and without Bowel Disease. Kidney International. 2003.
14. Borghi L et al. Urinary Volume, Water and Recurrences in Idiopathic Calcium Nephrolithiasis: A 5-Year Randomized Prospective Study. Journal of Urology. 1996.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Urocit-K is a registered trademark of Mission Pharmacal. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.